logo
logo

ReAlta Life Sciences Closes $14 Million Series A2 Financing to Support Transition into a Clinical Organization

ReAlta Life Sciences Closes $14 Million Series A2 Financing to Support Transition into a Clinical Organization

04/21/20, 12:31 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgnorfolk
Money raised
$14 million
Round Type
series a
ReAlta Life Sciences, Inc., today announced that it has successfully closed an oversubscribed Series A2 financing of $14 million, bringing the total Series A financing to $26 million. The financings were led by Children’s Research Holdings and Marathon Pharma, as well as additional undisclosed investors. ReAlta Life Sciences is a biotech company dedicated to harnessing the power of the immune system through its PIC1 technology platform to address life-threatening medical needs.

Company Info

Company
Re Alta Life Sciences
Location
norfolk, virginia, united states
Additional Info
ReAlta Life Sciences, Inc. is a biotech company dedicated to harnessing the power of the immune system through its PIC1 technology platform, comprised of a family of over 160 engineered peptides, to address life-threatening medical needs. To support its vision, ReAlta has developed a novel class of therapeutics with a dual targeting approach designed to rebalance complement and inflammatory processes in the body. The company’s pipeline is led by RLS-0071 (PIC1-dPEG24), which has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of hypoxic-ischemic encephalopathy (HIE) in neonates. The company launched in 2018, and is located in Norfolk, Virginia. For more information, please visit www.realtalifesciences.com.